Understanding the Voting Rights and Share Capital of Nanobiotix
In the world of corporate governance, voting rights are essential as they allow shareholders to influence key decisions that affect the company. Nanobiotix, a progressive clinical biotechnology firm, is dedicated to pushing the boundaries of medical treatments. This undertaking is crucial as it strives to improve patient outcomes through innovative health solutions.
Overview of Share Capital
Nanobiotix, established in 2003 and headquartered in Paris, has a robust share capital structure designed to support its ambitious goals in biotechnology. As of the latest update, the company has a total of 47,426,851 shares outstanding, creating an environment for extensive shareholder participation and engagement in decision-making processes.
Voting Rights Breakdown
The recent data illustrates that Nanobiotix presently holds approximately 49,529,244 theoretical voting rights, with about 49,507,126 of those being exercisable at shareholder meetings. This distribution reflects the company's commitment to transparency and inclusivity, encouraging stakeholders to actively voice their opinions during significant decisions.
About Nanobiotix
Nanobiotix is on the cutting edge of biotechnology, focusing on developing disruptive therapeutic techniques. The company's primary goal revolves around utilizing physics-based solutions to reshape treatment paradigms for thousands of patients worldwide. Their philosophy hinges on the belief that exploring beyond existing knowledge can create new opportunities for improving health outcomes.
Since its inception, Nanobiotix has cultivated a portfolio of over 25 patent families linked to three innovative nanotechnology platforms aimed at various medical applications: oncology, bioavailability, biodistribution, and CNS disorders. The evolution of these platforms signifies the company’s relentless pursuit of advancements in cancer treatment and neurological care.
Global Presence and Future Prospects
Nanobiotix's reach extends beyond Europe, as its subsidiary in Cambridge, Massachusetts, exemplifies its international influence in the biotechnology sector. The firm has been listed on the Euronext Paris since 2012 and made its debut on the Nasdaq Global Select Market in December 2020, highlighting its growth and credibility within the market.
Investors and stakeholders are encouraged to keep a close watch on Nanobiotix, especially with their ambitious pipeline aimed at innovative treatments that could add significant value to the healthcare landscape. Their ongoing commitment to research and development positions them favorably in a competitive environment.
Contact Information
If you wish to learn more about Nanobiotix or require additional information, the company has dedicated departments to facilitate communication.
Communications Department
Brandon Owens, VP, Communications
Phone: +1 (617) 852-4835
Email: contact@nanobiotix.com
Investor Relations Department
Ricky Bhajun, Director, Investor Relations
Email: investors@nanobiotix.com
Frequently Asked Questions
What are the voting rights of Nanobiotix shareholders?
Shareholders of Nanobiotix have voting rights that amount to approximately 49,529,244 theoretical rights, with 49,507,126 being exercisable.
Why is share capital important for Nanobiotix?
Share capital allows Nanobiotix to support its operational goals and engage shareholders in crucial decisions affecting the company's strategies and future.
How is Nanobiotix expanding its global presence?
Nanobiotix is expanding its global footprint by maintaining subsidiaries in strategic locations, reinforcing its position in the biotechnology industry.
What technologies does Nanobiotix focus on?
The company emphasizes three nanotechnology platforms, specifically targeting oncology, bioavailability, and central nervous system disorders.
How can I reach out to Nanobiotix for more information?
You can contact their communications or investor relations departments through the provided email addresses for inquiries or information requests.
